Sentences with phrase «myeloma cells as»

The new immune system that grows from the donor stem cells can recognize myeloma cells as «foreign» and kill them, which is known as the «graft - vs - myeloma» effect.

Not exact matches

In our study, as BMI increased, we started seeing an increase in the ability of multiple myeloma cells to adhere, which causes the cancer to better anchor,» DeCicco - Skinner explained.

As a patient's BMI increases, fat cells communicate with multiple myeloma cells, researchers found.

«The treatment of multiple myeloma has improved significantly in recent years with the introduction of therapies such as proteasome inhibitors [which interfere with tumor cells» protein - disposal system] and potent immuno - modulatory agents,» said the paper's senior author and lead investigator, Paul Richardson, MD, clinical program leader and director of clinical research at Dana - Farber's Jerome Lipper Multiple Myeloma Center, and the R.J. Corman professor at Harvard Medical myeloma has improved significantly in recent years with the introduction of therapies such as proteasome inhibitors [which interfere with tumor cells» protein - disposal system] and potent immuno - modulatory agents,» said the paper's senior author and lead investigator, Paul Richardson, MD, clinical program leader and director of clinical research at Dana - Farber's Jerome Lipper Multiple Myeloma Center, and the R.J. Corman professor at Harvard Medical Myeloma Center, and the R.J. Corman professor at Harvard Medical School.

The scientists discovered that dinaciclib, by interfering with UPR activation, caused multiple myeloma and myeloid leukemia cells to initiate a form of cell suicide known as apoptosis when exposed to agents that induced ER stress.

Although myeloma is, like leukemias and lymphomas, a cancer involving white blood cells known as lymphocytes, myeloma cells don't traditionally express CD19 on their surface because they arise from the most mature type of lymphocytes — plasma cells.

The company is developing CAR T - cell immunotherapies for multiple myeloma, prostate and other cancer types, as well as gene therapies for orphan diseases.

Plerixafor has been approved by the FDA as the first small - molecule CXCR4 antagonist for use in combination with granulocyte - colony stimulating factor (GCSF) to mobilize hematopoietic stem cells to the bloodstream for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma and multiple myeloma.

Cancers of the breast, prostate, colorectal system, liver and kidney as well as multiple myeloma, a cancer of the plasma cells that make antibodies to fight viruses and bacteria, strike earlier, deadlier and more often in some racial and ethnic groups, the National Cancer Institute has shown.

Myeloma — also referred to as multiple myeloma or plasma cell myeloma — is a cancer that originates in plasma cells, a type of white blood cell that makes antiMyeloma — also referred to as multiple myeloma or plasma cell myeloma — is a cancer that originates in plasma cells, a type of white blood cell that makes antimyeloma or plasma cell myeloma — is a cancer that originates in plasma cells, a type of white blood cell that makes antimyeloma — is a cancer that originates in plasma cells, a type of white blood cell that makes antibodies.

They fused mouse B cells — antibody - producing cells of the immune system — with human myeloma (also known as B cell cancer) cell lines in a new technique called hybridoma technology.

As the number of multiple myeloma cells increases, more antibodies are made.

No Place Like Home Rebecca Zoltoski was the first patient at the University of Chicago Medicine to undergo a blood and bone marrow stem cell transplant as an outpatient for her multiple myeloma.

Myeloma — also referred to as multiple myeloma or plasma cell myeloma — is a cancer that originates in plasma cells, a type of white blood cell that make antiMyeloma — also referred to as multiple myeloma or plasma cell myeloma — is a cancer that originates in plasma cells, a type of white blood cell that make antimyeloma or plasma cell myeloma — is a cancer that originates in plasma cells, a type of white blood cell that make antimyeloma — is a cancer that originates in plasma cells, a type of white blood cell that make antibodies.

This is in accordance with previous reports that decitabine and 5 - azacytidine produce a marked synergistic effect in combination with suberoylanilide hydroxamic acid and romidepsin in T - lymphoma cell lines by modulating cell cycle arrest and apoptosis.26, 27 As a mechanism of action, KMT2D mutations of B - lymphoma cells promote malignant outgrowth by perturbing methylation of H3K4 that affect the JAK - STAT, Toll - like receptor, or B - cell receptor pathway.28, 29 Here our study indicated that dual treatment with chidamide and decitabine enhanced the interaction of KMT2D with the transcription factor PU.1, thereby inactivating the H3K4me - associated signaling pathway MAPK, which is constitutively activated in T - cell lymphoma.13, 30,31 The transcription factor PU.1 is involved in the development of all hematopoietic lineages32 and regulates lymphoid cell growth and transformation.33 Aberrant PU.1 expression promotes acute myeloid leukemia and is related to the pathogenesis of multiple myeloma via the MAPK pathway.34, 35 On the other hand, PU.1 is also shown to interact with chromatin remodeler and DNA methyltransferease to control hematopoiesis and suppress leukemia.36 Our data thus suggested that the combined action of chidamide and decitabine may interfere with the differentiation and / or viability of PTCL - NOS through a PU.1 - dependent gene expression program.

No Association Between Response Rates and Survival in Newly Diagnosed Multiple Myeloma: Results of a recent meta - regression analysis of 63 randomized clinical trials out of Greece concluded that there was no association between conventional response outcomes, such as complete response (CR) or very good partial response (VGPR), and overall (OS) or progression - free survival (PFS) in patients with newly diagnosed multiple myeloma in populations of patients who received stem cell transplant and those who dMyeloma: Results of a recent meta - regression analysis of 63 randomized clinical trials out of Greece concluded that there was no association between conventional response outcomes, such as complete response (CR) or very good partial response (VGPR), and overall (OS) or progression - free survival (PFS) in patients with newly diagnosed multiple myeloma in populations of patients who received stem cell transplant and those who dmyeloma in populations of patients who received stem cell transplant and those who did not.

Though monoclonal antibodies were a model product in his 18 years CMO experience, process development was also performed for enzymes, hormones, blood factors, immuno - modulants and vaccines with different expression systems such as hybridoma, myeloma, CHO, BHK, insect - cell / baculovirus, adherent animal and human cells.

Additionally, for many blood cell malignancies such as certain types of leukaemia and multiple myeloma, HSC transplantation is an important therapeutic option.